Skip to main content
. 2018 Oct 12;33(4):969–980. doi: 10.1038/s41375-018-0276-9

Fig. 4.

Fig. 4

Investigator-assessed PFS by MRD level for a ibrutinib+BR and b placebo+BR arms. BR bendamustine and rituximab, MRD minimal residual disease, PFS progression-free survival